Provectus Biopharmaceuticals Establishes Research Collaboration with University of Tennessee Health Science Center to Investigate Small Molecule Rose Bengal Disodium for Antibiotic Resistance
KNOXVILLE, TN, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the Company has initiated a new sponsored research program with Michio Kurosu, PhD, Professor, Department of Pharmaceutical Sciences at the College of Pharmacy of the University of Tennessee Health Science Center (UTHSC) in Memphis, Tennessee to investigate rose bengal disodium (RBD) targeting of multi-drug resistant (MDR) bacteria. RBD is Provectus’ proprietary lead molecule, and a member of a class of small molecules called halogenated xanthenes that is entirely and wholly owned by the Company.
Dr. Kurosu’s team will undertake in vitro studies on:
- The spectrum of RBD activity against drug-susceptible and drug-resistant bacterial strains,
- Synergistic activity of combinations of RBD and US Food and Drug Administration-approved antibiotics for Gram-negative bacteria,
- The mutation frequency of RBD against bacterial strains, measuring spontaneous bacterial mutations for RBD and these combinations, and
- Gene analyses of mutant bacterial strains to understand resistance mechanisms.
Each year, according to the Centers for Disease Control and Prevention, drug-resistant bacteria and fungi kill more than 35,000 Americans, while more than 2.8 million Americans are infected with antibiotic-resistant bacteria.1
Provectus’ current Good Manufacturing Practices (cGMP) RBD is a proprietary pharmaceutical-grade drug substance produced by the Company’s quality-by-design (QbD) manufacturing process to exacting regulatory standards that avoids the formation of uncontrolled impurities currently present in commercial-grade rose bengal. Provectus’ RBD and cGMP RBD manufacturing process are protected by composition of matter and manufacturing patents as well as trade secrets.
Dominic Rodrigues, Vice Chair of the Company’s Board of Directors said, “The initiation of this antibiotic resistance research is another aspect of our ongoing work to investigate and demonstrate rose bengal disodium’s unique mechanistic properties and behavior across different disease areas and disease indications. Such work is fundamental to the continued expansion of Provectus’ drug product platform, where disease-specific formulations of rose bengal disodium can be delivered by oral, intralesional, topical, and potentially other routes of administration.”
About Rose Bengal Disodium
RBD is 4,5,6,7-tetrachloro-2’,4’,5’,7’-tetraiodofluorescein disodium, a halogenated xanthene and Provectus’ proprietary lead molecule. The Company manufactures cGMP RBD using a patented process designed to meet stringent modern global quality requirements for pharmaceuticals and pharmaceutical ingredients.
An intralesional (IL) formulation (i.e., by direct injection) of cGMP RBD drug substance, cGMP PV-10®, is being developed as a clinical-stage autolytic immunotherapy drug product for solid tumor cancers. By targeting tumor cell lysosomes, RBD treatment may yield immunogenic cell death in solid tumor cancers that results in tumor-specific reactivity in circulating T cells and a T cell mediated immune response against treatment refractory and immunologically cold tumors.2-4 Adaptive immunity can be enhanced by combining immune checkpoint blockade (CB) with RBD.5 IL PV-10 is undergoing clinical study for relapsed and refractory adult solid tumor cancers, such skin and liver cancers.
IL PV-10 is also undergoing preclinical study for relapsed and refractory pediatric solid tumor cancers, such as neuroblastoma, Ewing sarcoma, rhabdomyosarcoma, and osteosarcoma6,7.
A topical formulation of cGMP RBD drug substance, PH-10®, is being developed as a clinical-stage immuno-dermatology drug product for inflammatory dermatoses, such as atopic dermatitis and psoriasis. RBD can modulate multiple interleukin and interferon pathways and key cytokine disease drivers.8
Oral formulations of cGMP RBD are undergoing preclinical study for relapsed and refractory pediatric blood cancers, such as acute lymphocytic leukemia and acute myelomonocytic leukemia9,10.
Oral formulations of cGMP RBD are undergoing preclinical study as prophylactic and therapeutic treatments for high-risk adult solid tumor cancers, such as head and neck, breast, pancreatic, liver, and colorectal cancers.
Intellectual Property (IP)
Provectus’ IP includes a family of US and international (a number of countries in Asia, Europe, and North America) patents that protect the process by which cGMP RBD and related halogenated xanthenes are produced, avoiding the formation of previously unknown impurities that exist in commercial-grade rose bengal in uncontrolled amounts. The requirement to control these impurities is in accordance with International Council on Harmonisation (ICH) guidelines for the manufacturing of a pharmaceutical. US patent numbers are , , and , with expirations ranging from 2030 to 2031.
About Provectus
Provectus Biopharmaceuticals, Inc. (Provectus or the Company) is a clinical-stage biotechnology company developing immunotherapy medicines for different disease areas based on an entirely- and wholly-owned family of small molecules called halogenated xanthenes. Information about the Company’s clinical trials can be found at the NIH registry, . For additional information about Provectus, please visit the Company's website at .
References
1. Greg Frank OC. . TheHill. Published August 20, 2020.
2. Wachter et al. . Proceedings of SPIE 4620, 143, 2002.
3. Liu et al. . Oncotarget 7, 37893, 2016.
4. Qin et al. . Cell Death and Disease 8, e2584, 2017.
5. Liu et al. . PLoS One 13, e0196033, 2018.
6. Swift et al. . OncoTargets and Therapy 12, 1293, 2019.
7. Swift et al. . 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, Journal of Clinical Oncology 36, 2018 (suppl; abstr 10557).
8. Krueger et al. . Psoriasis Gene to Clinic, 8th International Congress, British Journal of Dermatology 177.
9. Swift et al. . 2018 American Society of Hematology (ASH) Annual Meeting, Blood 132, 2018 (suppl; abstr 5207).
10. Thakur et al. . 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II, (abstr 5393).
Trademarks
PV-10® and PH-10® are registered trademarks of Provectus, Knoxville, Tennessee, U.S.A.
FORWARD-LOOKING STATEMENTS: The information in this press release may include “forward-looking statements,” within the meaning of U.S. securities legislation, relating to the business of Provectus and its affiliates, which are based on the opinions and estimates of Company management and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “seek,” “anticipate,” “budget,” “plan,” “continue,” “estimate,” “expect,” “forecast,” “may,” “will,” “project,” “predict,” “potential,” “targeting,” “intend,” “could,” “might,” “should,” “believe,” and similar words suggesting future outcomes or statements regarding an outlook.
The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated or that such agents as products will achieve any particular revenue levels.
Due to the risks, uncertainties, and assumptions inherent in forward-looking statements, readers should not place undue reliance on these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof or as of the date specifically specified herein, and Provectus undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except in accordance with applicable securities laws. The forward-looking statements are expressly qualified by this cautionary statement.
Risks, uncertainties, and assumptions include those discussed in the Company’s filings with the SEC, including those described in and .
###
Contact:
Provectus Biopharmaceuticals, Inc.
Heather Raines, CPA
Chief Financial Officer
Phone: (866) 594-5999
